EXHIBIT A
Claims as Pending Following Entry of the Amendments Made Herein
(Application No. 09/724,530; Attorney Docket No. 9632-012)

26. A method for the treatment or prevention of cancer in a subject comprising: administering to the subject an amount of a molecule comprising SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, which molecule (i) immunospecifically binds CD40, (ii) increases the binding of CD40 ligand to CD40 by at least 45%, and (iii) comprises one or more substitutions or insertions in primary amino acid sequence relative to native monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, which amount is effective for the treatment or prevention of cancer.

27. A method for the treatment or prevention of cancer in a subject comprising: administering to the subject an amount of a purified protein, which protein (i) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, (ii) increases the binding of CD40 ligand to CD40 by at least 45%, and (iii) comprises one or more substitutions or insertions in primary amino acid sequence relative to native monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, which amount is effective for the treatment or prevention of cancer.

32. The method of any one of claims 26 or 27 further comprising administering CD40 ligand to the subject.

33. The method of any one of claims 26 or 27 in which the subject is a human.

37. A method for the treatment or prevention of cancer or an immune disorder in a subject comprising administering to the subject, in an amount effective for said treatment or prevention: (a) a molecule that immunospecifically binds CD40, which molecule increases the binding of CD40 ligand to CD40; and (b) CD40 ligand.

38. (New) The method of claim 26, wherein the molecule is conjugated to a chemotherapeutic agent.

39. (New) The method of claim 27, wherein the protein is conjugated to a chemotherapeutic agent.

40. (New) The method of claim 37, wherein the molecule is conjugated to a chemotherapeutic agent.

41. (New) The method of claim 26 or 37, wherein the molecule is purified.

42. (New) The method of any one of claims 38-40, where the subject is a human.

43. (New) The method of claim 26, wherein the molecule is purified, further comprising administering CD40 ligand to the subject.

44. (New) The method of claim 26 or 37, wherein the molecule is a protein.

45. (New) The method of claim 44, wherein the protein is an antibody.

46. (New) The method of claim 45, wherein the antibody comprises a human constant region.

47. (New) The method of claim 46, wherein the antibody is a chimeric antibody.

48. (New) The method of claim 46, wherein the antibody is a humanized antibody.

49. (New) The method of claim 46, wherein the antibody is a human antibody.

50. (New) The method of claim 45, wherein the antibody is purified.

51. (New) The method of claim 50, further comprising administering CD40 ligand to the subject.

52. (New) The method of claim 27, wherein the protein is an antibody.

53. (New) The method of claim 52, wherein the antibody comprises a human constant region.

54. (New) The method of claim 53, wherein the antibody is a chimeric antibody.

55. (New) The method of claim 53, wherein the antibody is a humanized antibody.

56. (New) The method of claim 53, wherein the antibody is a human antibody.

57. (New) The method of claim 52, further comprising administering CD40 ligand to the subject.